Cannabinoid Encyclopedia

Cannabinoid guide

What is THCV?

A clear guide to THCV: what it is, what researchers have studied, how strong the evidence is, and what to know about safety.

Updated July 2026 63 research sources Human and early research

The short answer

THCV, in simple terms

THCV, short for tetrahydrocannabivarin, is a plant cannabinoid with chemistry related to THC but a different research profile. Researchers study it for possible effects, safety, and how it works in the body. The source set includes human research as well as earlier-stage studies. The evidence does not turn this into one proven benefit, because studies can use different products, doses, routes, people, and outcomes. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about THCV.

Why people look into itSee the main questions before the research details. What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Why people look into THCV

What THCV is commonly talked about for

These cards show the questions most represented in this source set. They are not a list of proven benefits, and the evidence label matters as much as the topic name.

  1. Mostly mechanism-focused

    Receptor, target, metabolic, and pharmacology mechanisms

    Researchers have looked at THCV in appetite or metabolism-related models. That does not show that it changes appetite, weight, or metabolism for people. 3

    See research areas

  2. Human and early-stage research

    Appetite and metabolic outcomes

    Researchers have looked at THCV in appetite or metabolism-related models. That does not show that it changes appetite, weight, or metabolism for people. 4

    See research areas

  3. Human and early-stage research

    Pain-related outcomes

    People look at THCV for pain because the literature includes pain models, sensory signaling, or related pharmacology. That does not establish pain relief in people. 3

    See research areas

  4. Mostly mechanism-focused

    Inflammation-related outcomes

    Interest in THCV and inflammation comes from studies of inflammatory or immune signals. A change in a laboratory or animal model is not proof of a human treatment effect. 6

    See research areas

  5. Human and early-stage research

    Safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns

    Safety research asks how THCV, its dose, route, formulation, and other medications may change risk. The available evidence may not answer the safety question for every product or person. 2

    See research areas

Bottom line: Start with the exact question you care about, then check the study type, product, dose, and outcome before treating a research signal as a real-world effect.

Key takeaways

What to know first

  1. 1

    Research on THCV covers Safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns, Receptor, target, metabolic, and pharmacology mechanisms, and Appetite and metabolic outcomes; those areas should not be combined into one claim. 1

  2. 2

    The source set includes human research as well as earlier-stage studies. 2

  3. 3

    Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3

Research areas

What has THCV been studied for?

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Human and early-stage research

Safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns

Researchers have examined THCV in connection with Safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns. The studies may differ in compound, formulation, dose, route, population, and outcome. 2

Mostly mechanism-focused

Receptor, target, metabolic, and pharmacology mechanisms

Studies connect THCV with Receptor, target, metabolic, and pharmacology mechanisms at the level of receptors, enzymes, signaling, or pharmacology. This helps explain how the biology might work, but it does not prove a health outcome. 3

Human and early-stage research

Appetite and metabolic outcomes

Researchers have examined THCV in connection with Appetite and metabolic outcomes. The studies may differ in compound, formulation, dose, route, population, and outcome. 4

Human and early-stage research

Pain-related outcomes

Researchers have examined THCV in connection with Pain-related outcomes. The studies may differ in compound, formulation, dose, route, population, and outcome. 3

Human and early-stage research

Neurobehavioral, cognition, mood, reward, or THC-interaction outcomes

Researchers have examined THCV in connection with Neurobehavioral, cognition, mood, reward, or THC-interaction outcomes. The studies may differ in compound, formulation, dose, route, population, and outcome. 5

Mostly mechanism-focused

Inflammation-related outcomes

Researchers have examined THCV in connection with Inflammation-related outcomes. The studies may differ in compound, formulation, dose, route, population, and outcome. 6

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

20 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

14 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

23 sources

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

Another 6 of 63 research sources could not be placed cleanly into those three groups from the recorded study details.

What these studies actually looked at

The research on THCV is not one kind of study. This source set includes 19 animal studies, 13 narrative or expert reviews, 9 clinical studies in people, and 7 cell or laboratory studies. 3

The recorded populations or models include people or patients (24 sources), animal models (14 sources), and cells or tissue models (8 sources). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns (24 sources), receptor, target, metabolic, or pharmacology mechanisms (23 sources), and appetite-related or metabolic outcomes (13 sources). Closely related outcome names can still describe different measurements. 5

The THCV source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

systematic review or meta-analysis

Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.

On this page, this source examines THCV activity involving receptor, target, metabolic, or pharmacology mechanisms. 1

Study type
systematic review or meta-analysis
Population or model
cells or tissue models
Outcome focus
receptor, target, metabolic, or pharmacology mechanisms
Evidence stage
evidence still limited

narrative or expert review

The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management.

On this page, this source examines THCV and appetite and metabolic outcomes and THCV and safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns. 2

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
appetite-related or metabolic outcomes and safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns
Evidence stage
evidence still limited

narrative or expert review

It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.

On this page, this source examines THCV and appetite and metabolic outcomes, THCV activity involving receptor, target, metabolic, or pharmacology mechanisms, and THCV and pain-related outcomes. 3

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
appetite-related or metabolic outcomes and receptor, target, metabolic, or pharmacology mechanisms and other recorded details
Evidence stage
evidence still limited

clinical study in people

Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes.

On this page, this source examines THCV and appetite and metabolic outcomes. 4

Study type
clinical study in people
Population or model
people or patients
Outcome focus
appetite-related or metabolic outcomes
Evidence stage
human research

narrative or expert review

Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.

On this page, this source examines THCV and safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns, THCV activity involving receptor, target, metabolic, or pharmacology mechanisms, and THCV and neurobehavioral, cognition, mood, reward, or THC-interaction outcomes. 5

Study type
narrative or expert review
Population or model
cells or tissue models
Outcome focus
safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns and receptor, target, metabolic, or pharmacology mechanisms and other recorded details
Evidence stage
evidence still limited

Safety and limits

What should readers keep in mind?

Research on THCV should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 2

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

What is THCV?

THCV is a cannabinoid-related compound studied across Safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns, Receptor, target, metabolic, and pharmacology mechanisms, Appetite and metabolic outcomes, and Pain-related outcomes. This page separates those research questions so they are not mistaken for one broad claim. 7

What has THCV been studied for?

The current source set includes Safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns, Receptor, target, metabolic, and pharmacology mechanisms, Appetite and metabolic outcomes, and Pain-related outcomes. Each area may use different doses, products, routes, populations, and outcome measures. 8

How strong is the research on THCV?

The source set includes human research as well as earlier-stage studies. 9

Is THCV safe?

Safety cannot be answered for THCV without context. Dose, route, formulation, medications, and the person using it can all change risk. 10

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. systematic review or meta-analysis; evidence still limited PubMed 25257544 DOI 10.1111/bph.12944
  2. 2
    The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management. narrative or expert review; evidence still limited PubMed 40270953 DOI 10.3934/neuroscience.2025003
  3. 3
    It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets. narrative or expert review; evidence still limited PubMed 32899626 DOI 10.3390/molecules25184036
  4. 4
    Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes. clinical study in people; human research PubMed 33526143 DOI 10.1186/s42238-020-0016-7
  5. 5
    Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management. narrative or expert review; evidence still limited PubMed 40872492 DOI 10.3390/ph18081101
  6. 6
    Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages. cell or laboratory study; mechanism-focused research PubMed 37764262 DOI 10.3390/molecules28186487
  7. 7
    Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. animal study; mechanism-focused research PubMed 27498155 DOI 10.1016/j.phrs.2016.07.045
  8. 8
    A Two-Phase, Dose-Ranging, Placebo-Controlled Study of the Safety and Preliminary Test of Acute Effects of Oral Δ8-Tetrahydrocannabivarin in Healthy Participants. clinical study in people; human research PubMed 37721990 DOI 10.1089/can.2023.0038
  9. 9
    Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study. clinical study in people; human research PubMed 11599601 DOI 10.1093/jat/25.7.565
  10. 10
    Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. clinical study in people; mechanism-focused research PubMed 27573936 DOI 10.2337/dc16-0650
  11. 11
    Medical use of cannabis. Cannabidiol: a new light for schizophrenia? clinical study in people; evidence still limited PubMed 23109356 DOI 10.1002/dta.1425
  12. 12
    Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers. clinical study in people; evidence still limited; mechanism-focused research PubMed 25542687 DOI 10.1093/ijnp/pyu094
See all 63 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes. clinical study in people; human research / 1 linked research note PubMed 33526143
  2. The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management. narrative or expert review; evidence still limited / 2 linked research notes PubMed 40270953
  3. It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets. narrative or expert review; evidence still limited / 3 linked research notes PubMed 32899626
  4. Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. clinical study in people; mechanism-focused research / 2 linked research notes PubMed 27573936
  5. CB₁-independent mechanisms of Δ⁹-THCV, AM251 and SR141716 (rimonabant). narrative or expert review; evidence still limited / 2 linked research notes PubMed 21740450
  6. SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity. cell or laboratory study; mechanism-focused research / 3 linked research notes PubMed 42196303
  7. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. animal study; mechanism-focused research / 2 linked research notes PubMed 33230154
  8. Weight Loss and Therapeutic Metabolic Effects of Tetrahydrocannabivarin (THCV)-Infused Mucoadhesive Strips. clinical study in people; mechanism-focused research / 1 linked research note PubMed 39968488
  9. The Impact of Major and Minor Phytocannabinoids on the Maintenance and Function of INS-1 β-Cells Under High-Glucose and High-Lipid Conditions. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 40363798
  10. Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study. clinical study in people; human research / 1 linked research note PubMed 11599601
  11. Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. animal study; mechanism-focused research / 4 linked research notes PubMed 27498155
  12. Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages. cell or laboratory study; mechanism-focused research / 3 linked research notes PubMed 37764262
  13. Tetrahydrocannabivarin (THCV) Protects Adipose-Derived Mesenchymal Stem Cells (ASC) against Endoplasmic Reticulum Stress Development and Reduces Inflammation during Adipogenesis. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 37108282
  14. High fat-fed GPR55 null mice display impaired glucose tolerance without concomitant changes in energy balance or insulin sensitivity but are less responsive to the effects of the cannabinoids rimonabant or Δ(9)-tetrahydrocannabivarin on weight gain. animal study; mechanism-focused research / 1 linked research note PubMed 32904155
  15. Investigational cannabinoids in seizure disorders, what have we learned thus far? narrative or expert review; evidence still limited / 1 linked research note PubMed 29842819
  16. Ultrafast, Selective, and Highly Sensitive Nonchromatographic Analysis of Fourteen Cannabinoids in Cannabis Extracts, Δ8-Tetrahydrocannabinol Synthetic Mixtures, and Edibles by Cyclic Ion Mobility Spectrometry-Mass Spectrometry. evidence still limited / 1 linked research note PubMed 38862388
  17. Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management. narrative or expert review; evidence still limited / 3 linked research notes PubMed 40872492
  18. Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review. narrative or expert review; evidence still limited / 1 linked research note PubMed 37630401
  19. Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats. animal study; preclinical research / 1 linked research note PubMed 37721989
  20. A Two-Phase, Dose-Ranging, Placebo-Controlled Study of the Safety and Preliminary Test of Acute Effects of Oral Δ8-Tetrahydrocannabivarin in Healthy Participants. clinical study in people; human research / 1 linked research note PubMed 37721990
  21. Effect of cannabinol, tetrahydrocannabivarin and cannabidiol on voluntary alcohol consumption. animal study; mechanism-focused research / 1 linked research note PubMed 41947574
  22. Effect of cannabidiol, cannabinol and tetrahydrocannabivarin in managing inflammatory pain. animal study; preclinical research / 2 linked research notes PubMed 42151379
  23. Prevalence of ∆8-tetrahydrocannabinol carboxylic acid in workplace drug testing. evidence still limited / 1 linked research note PubMed 37697897
  24. Examining impairment and kinetic patterns associated with recent use of hemp-derived Δ8-tetrahydrocannabinol: case studies. evidence still limited / 1 linked research note PubMed 35799289
  25. Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers. clinical study in people; evidence still limited; mechanism-focused research / 3 linked research notes PubMed 25542687
  26. The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. clinical study in people; mechanism-focused research / 2 linked research notes PubMed 26577065
  27. Hair Regrowth with Novel Hemp Extract: A Case Series. case report or case series; mechanism-focused research / 1 linked research note PubMed 37305187
  28. Differences in Online Descriptions and Marketing of Derived Intoxicating Cannabis Products. evidence still limited / 1 linked research note PubMed 40131178
  29. Role of Cannabidiol and Tetrahydrocannabivarin on Paclitaxel-induced neuropathic pain in rodents. animal study; evidence still limited / 1 linked research note PubMed 35303507
  30. The cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. animal study; mechanism-focused research / 1 linked research note PubMed 23712280
  31. Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders. narrative or expert review; evidence still limited / 1 linked research note PubMed 31549358
  32. Cannabinoids and terpenes for diabetes mellitus and its complications: from mechanisms to new therapies. narrative or expert review; evidence still limited / 1 linked research note PubMed 36280497
  33. Indeterminacy of cannabis impairment and ∆9-tetrahydrocannabinol (∆9-THC) levels in blood and breath. evidence still limited / 1 linked research note PubMed 35585089
  34. Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. evidence still limited / 1 linked research note PubMed 23894589
  35. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. narrative or expert review; evidence still limited / 1 linked research note PubMed 17828291
  36. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. animal study; mechanism-focused research / 1 linked research note PubMed 21175579
  37. Molecular Pharmacology of Phytocannabinoids. narrative or expert review; evidence still limited / 1 linked research note PubMed 28120231
  38. Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 25257544
  39. Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. animal study; mechanism-focused research / 1 linked research note PubMed 16205722
  40. Pharmacology of cannabinoids in the treatment of epilepsy. narrative or expert review; evidence still limited / 1 linked research note PubMed 28087250
  41. Tetrahydrocannabivarin (THCV) Dose Dependently Blocks or Substitutes for Tetrahydrocannabinol (THC) in a Drug Discrimination Task in Rats. animal study; mechanism-focused research / 1 linked research note PubMed 41008636
  42. Δ9-tetrahydrocannabivarin impairs epithelial calcium transport through inhibition of TRPV5 and TRPV6. mechanism-focused research / 1 linked research note PubMed 30170189
  43. Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence. animal study; mechanism-focused research / 2 linked research notes PubMed 31454413
  44. The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. animal study; mechanism-focused research / 2 linked research notes PubMed 20590571
  45. The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo. animal study; mechanism-focused research / 2 linked research notes PubMed 17245367
  46. Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats. animal study; mechanism-focused research / 1 linked research note PubMed 23902479
  47. The phytocannabinoid Delta(9)-tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum. animal study; mechanism-focused research / 1 linked research note PubMed 18311186
  48. TRPV3 activation by different agonists accompanied by lipid dissociation from the vanilloid site. mechanism-focused research / 2 linked research notes PubMed 38691614
  49. Loratadine, an antihistaminic drug, suppresses the proliferation of endometrial stromal cells by inhibition of TRPV2. animal study; mechanism-focused research / 1 linked research note PubMed 35714693
  50. Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. animal study; mechanism-focused research / 1 linked research note PubMed 21726418
  51. An Evaluation of Understudied Phytocannabinoids and Their Effects in Two Neuronal Models. mechanism-focused research / 1 linked research note PubMed 34500785
  52. Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice. animal study; mechanism-focused research / 1 linked research note PubMed 30074247
  53. Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 33446817
  54. Phytocannabinoids Act Synergistically with Non-Steroidal Anti-Inflammatory Drugs Reducing Inflammation in 2D and 3D In Vitro Models. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 36559009
  55. Neuroimaging studies towards understanding the central effects of pharmacological cannabis products on patients with epilepsy. narrative or expert review; evidence still limited / 1 linked research note PubMed 28109780
  56. Medical use of cannabis. Cannabidiol: a new light for schizophrenia? clinical study in people; evidence still limited / 1 linked research note PubMed 23109356
  57. The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers. clinical study in people; human research / 1 linked research note PubMed 26362774
  58. Molecular pathway and structural mechanism of human oncochannel TRPV6 inhibition by the phytocannabinoid tetrahydrocannabivarin. cell or laboratory study; evidence still limited / 1 linked research note PubMed 37532722
  59. Exploring Cannabis sativa L for Anti-Alzheimer Potential: An Extensive Computational Study including Molecular Docking, Molecular Dynamics, and ADMET Assessments. mechanism-focused research / 1 linked research note PubMed 40525419
  60. Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception. mechanism-focused research / 1 linked research note PubMed 19679411
  61. Cannabivarin and tetrahydrocannabivarin modulate nociception via vanilloid channels and cannabinoid-like receptors in Caenorhabditis elegans. mechanism-focused research / 1 linked research note PubMed 41135090
  62. Quantification of Eight Cannabinoids Including Cannabidiol in Human Urine Via Liquid Chromatography Tandem Mass Spectrometry. human research / 1 linked research note PubMed 30350275
  63. The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. narrative or expert review; evidence still limited / 1 linked research note PubMed 22155112